2025 MOQC MEASURES | ||||
---|---|---|---|---|
Measure Number | Measure Description | Target | MEQC | VBR |
101b | Tobacco cessation counseling or referral for tobacco users once a year | 70 | X | X |
103 | Designated advocate documented on a legally recognized document in the inpatient or outpatient medical record | 20 | X | |
108a | Complete family history documented for patients with invasive cancer | 35 | X | |
114 | NK1RA administered for low or moderate emetic risk cycle 1 chemotherapy (lower score = better) | 10 | X | X |
115 | NK1RA and olanzapine prescribed or administered with high emetic risk chemotherapy | 60 | X | X |
126a | Hospice enrollment | 65 | X | |
126b | Hospice enrollment more than 7 days before death | 60 | X | |
126c | Hospice enrollment more than 30 days before death | 30 | X | |
127a | Any anticancer therapy, including chemotherapy, administered within the last 14 days of life (lower score = better) | |||
128 | Non-chemotherapy anticancer agent administered within the last 14 days of life (lower score = better) | |||
129 | Palliative care consultation more than 90 days before death | 20 | X | |
130 | Beginning a new anticancer regimen within the last 14 days of life (lower score = better) | 10 | X | |
GYNECOLOGIC ONCOLOGY ONLY MEASURES | ||||
Measure Number | Measure Description | Target | MEQC | VBR |
116 | Prescribing of opioids for patients after laparoscopic or open hysterectomy | 9 pills or fewer | X | X |
123 | Days from surgery to chemotherapy start | 28 days or less | X | X |